Phenylephrine/tropicamide - Eyenovia

Drug Profile

Phenylephrine/tropicamide - Eyenovia

Alternative Names: Dx 102; Tropicamide/phenylephrine - Eyenovia

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eyenovia
  • Class Antihyperglycaemics
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Mydriasis

Most Recent Events

  • 30 Oct 2017 Adverse events, pharmacokinetics and pharmacodynamics data from a phase II EYE 102 trial in Mydriasis released by Eyenovia
  • 30 Oct 2017 Eyenovia plans a phase III trials for Glaucoma, Mydriasis and Dry eye in 2018
  • 20 Dec 2016 Adverse events data from the phase II EYE 102 trial in Mydriasis released by Eyenovia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top